An observational study in Myocarditis, Pediatric Inflammatory Multisystem Syndrome and Kawasaki Disease, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 1 site in France. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-08-30.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Myocarditis with a site in France — 11 open to participants now, 13 under way, 2 of them phase 3. Myocarditis · France.
Among the 31 studies in Myocarditis with a site in France, this one is the 15th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2023, is one of 19 observational ones, reaches primary completion later than 0 of the 12 other live ones, and was the 26th registered.
175 studies on the registry are indexed under Myocarditis; 75 are open to participants now.
Browse Myocarditis studies →11 of the 31 studies in Myocarditis with a site in France are open now. Recruiting first, the newest first:
Groupe Hospitalier Pitie-Salpetriere · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
Central Hospital, Nancy, France · Sites in France
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 53 Myocarditis studies recruiting now, 32 (60%) set no upper age limit and 6 (11%) stop at 75 or younger; 15 take children under 18; 14 take healthy volunteers.
This study: 0 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 3
First in 2016; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 200 across 121 observational studies indexed under Myocarditis.
Median enrollment 110 across the 12 interventional studies, 500 across the 19 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 31 have an industry lead sponsor. The 10 most frequent:
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
Central Hospital, Nancy, France has 3 studies filed under Myocarditis — fewer than ten, so there is no comparison to draw.
3 of the studies in Myocarditis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07077304Assistance Publique - Hôpitaux de ParisEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases | 2027-08-31 |
| NCT07633587Groupe Hospitalier Pitie-SalpetriereATROPOS: Survival Analysis of ICI-associated Myocarditis | 2027-10-01 |
| NCT03842592University Hospital, AngersVentricular Arrhythmia After Myocarditis in Sportsman | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Myocarditis with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Acquired inflammatory or infectious cardiac diseases, in pediatrics, include Kawasaki disease, myocarditis, and Covid-19-related Pediatric Multisystemic Inflammatory Syndrome (PIMS).
These 3 inflammatory cardiac diseases have clinical, biological, and echographic similarities and differences. Nevertheless their modalities of monitoring, management and evolution are different. The investigators wish to retrospectively analyze biological and echocardiographic data of Kawasaki disease, myocarditis, PIMS patients managed at Nancy Children Hospital from January 1, 2017 to June 31, 2023.
The primary objective of this study is to identify, for these 3 pathologies, the prognostic factors of initiation of inotropic support.
The secondary objective is to identify the prognostic factors of degradation of ventricular function.
age \< 18 years initial management and follow up in Nancy university children hospital center for PIMS Myocarditis and Kawasaki disease patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention Study of available clinical, biological, and echocardiographic data
Other: study of biological samples and echocardiographic data and link with need of hemodynamic support
No intervention Study of available clinical, biological, and echocardiographic data
Other: study of biological samples and echocardiographic data and link with need of hemodynamic support
No intervention Study of available clinical, biological, and echocardiographic data
Other: study of biological samples and echocardiographic data and link with need of hemodynamic support
observational study : there is no intervention
need of hemodynamic support
The need for haemodynamic support is defined dichotomously: yes or no. The investigators wish to identify the predictive factors of need for haemodynamic support among the following variables: groups (PIMS, KAWASAKI, MYOCARDITIS), cardiac biomarkers (troponin and NT-pro-BNP at admission (in ng/ml)) and echocardiographic criterias (Left Ventricular Ejection fraction, global and regional longitudinal strain at admission (in %)).
Time frame: up to 20 days
deterioration of Left Ventricular Ejection fraction
Left Ventricular Ejection fraction degradation is defined as an Left Ventricular Ejection fraction below the value of the first quartile of Left Ventricular Ejection fraction of all patients taken into account (Left Ventricular Ejection fraction as a percentage). The investigators wish to identify the predictive factors of Left Ventricular Ejection fraction degradation among the following variables: groups (PIMS, KAWASAKI, MYOCARDITIS), cardiac biomarkers (troponin and NT-pro-BNP at admission (in ng/ml)) and echocardiographic criterias (Left Ventricular Ejection fraction , global and regional longitudinal strain at admission (in %)).
Time frame: up to 20 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2023; primary completion for Sep 2023, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →